Neoleukin Therapeutics (NASDAQ:NLTX) Shares Down 5.6% - Should You Sell?

Key Points

• Neoleukin Therapeutics' stock fell by 5.6%, dropping to $19.22 after a recent closing price of $20.35.
• The trading volume significantly increased, with approximately 152,690 shares changing hands, marking a 205% rise compared to the average daily volume.
• Neoleukin Therapeutics focuses on developing immunotherapies for cancer and autoimmune disorders, with its lead candidate NL-201 targeting various cancer types.

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - )'s stock price was down 5.6% during trading on Wednesday . The company traded as low as $18.94 and last traded at $19.22. Approximately 152,690 shares changed hands during trading, an increase of 205% from the average daily volume of 50,104 shares. The stock had previously closed at $20.35.

Neoleukin Therapeutics Price Performance

The business has a 50 day moving average price of $20.45 and a 200 day moving average price of $17.16. The firm has a market capitalization of $180.63 million, a P/E ratio of -6.18 and a beta of 1.11.

About Neoleukin Therapeutics

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.